Results 191 to 200 of about 132,304 (290)

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

Acta Paediatrica, EarlyView.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner, Despina D. Briana, Gian Carlo Di Renzo   +2 more
wiley   +1 more source

Comparative evaluation of protective efficacy of experimental inactivated vaccines against haemorrhagic septicaemia. [PDF]

Braz J Microbiol
Dhakarwal P, Medhi M, Muthuchelvan D, Chaudhuri P, Viswas KN, Patel BHM, Shivachandra SB, Bhanuprakash V, Ramakrishnan MA.   +8 more
europepmc   +1 more source

The Safety and Efficacy of New DIVA Inactivated Vaccines Against Lumpy Skin Disease in Calves. [PDF]

Vaccines (Basel)
Ronchi GF, Iorio M, Serroni A, Caporale M, Testa L, Palucci C, Antonucci D, Capista S, Traini S, Pinoni C, Di Matteo I, Laguardia C, Armillotta G, Profeta F, Valleriani F, Di Felice E, Di Teodoro G, Sacchini F, Luciani M, Di Pancrazio C, Podaliri Vulpiani M, Rossi E, Salini R, Morelli D, Ferri N, Mercante MT, Di Ventura M.   +26 more
europepmc   +1 more source

Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques. [PDF]

Front Immunol, 2022
He Q, Mao Q, Zhang J, Gao F, Bai Y, Cui B, Liu J, An C, Wang Q, Yan X, Yang J, Song L, Song Z, Liu D, Yuan Y, Sun J, Zhao J, Bian L, Wu X, Huang W, Li C, Wang J, Liang Z, Xu M.   +23 more
europepmc   +1 more source

Malignant craniopharyngiomas: Institutional experience and literature review

Brain Pathology, EarlyView.
We report the second case of malignant craniopharyngioma with BAP1 and TP53 mutations. A literature review identified 44 cases of malignant craniopharyngiomas with a median overall survival of 6 months. Eighteen (41%) occurred in patients without any history of radiation, suggesting that mechanisms other than radiation have contributed to their ...
Thomas J. Auen, Isabella W. Zhang, Weiwei Zhang, Jordan M. Burr, Matthew L. Carda, James L. Wisecarver, Nicole Shonka, Jesse L. Cox, Sahara J. Cathcart, Allison Cushman‐Vokoun, Jie Chen   +10 more
wiley   +1 more source

Molecular characterization of avian pathogenic Escherichia coli strains in Jiangxi Province, China, and development of polyvalent inactivated vaccines. [PDF]

Poult Sci
Tan J, Wang YX, Kang ZF, Huang JN, Li HQ, Wu CC, Li N, Zhang FF, Tan MF.   +8 more
europepmc   +1 more source

Comparison of Safety of Different Vaccine Boosters Following Two-Dose Inactivated Vaccines: A Parallel Controlled Prospective Study. [PDF]

Vaccines (Basel), 2022
Lin ZQ, Wu JN, Huang RD, Xie FQ, Li JR, Zheng KC, Zhang DJ.   +6 more
europepmc   +1 more source

Synergistic antiviral activity against human adenovirus through combination of itraconazole and brincidofovir

British Journal of Pharmacology, EarlyView.
Background and Purpose Human adenovirus (HAdV) causes respiratory or gastrointestinal tract infections depending on the virus subtype. While HAdV infections are generally self‐limiting in immunocompetent people, they can result in significant morbidity and mortality in immunocompromised adults and children.
Mohamed Zamzamy, Sophie Post, Wing Hang Ip, Elin Hahlin, Sebastian Kühn, Andrea Pirosu, Christian Conze, Martin Baumdick, Hamburg Intestinal Study Group, Madeleine J. Bunders, Britta F. Zecher, Angelique Hoelzemer, Stephan Linder, Niklas Arnberg, Thomas Dobner, Marcus Altfeld, Sebastian Schloer   +16 more
wiley   +1 more source

Predicting SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cell responses elicited by inactivated vaccines in healthy adults using machine learning models. [PDF]

Clin Exp Med
Ning J, Ren Y, Zhang Z, Zeng X, Wang Q, Xie J, Xu Y, Fan Y, Li H, Zhai A, Li B, Wu C, Chen Y.   +12 more
europepmc   +1 more source

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial. [PDF]

Life Metab, 2023
Gui Y, Cao Y, He J, Zhao C, Zheng W, Qian L, Cheng J, Yu C, Yu C, Lou K, Liu G, Jia J.   +11 more
europepmc   +1 more source